Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Transcriptomic and Metabolomic Profiling Identifies Calcium-Dependent Signaling Mechanisms As a Novel and Exploitable Target to Overcome Anti-CD20 Resistance in Non-Hodgkin Lymphoma (NHL)

Ravi Dashnamoorthy, PhD, Saheli Sarkar, PhD, Afshin Beheshti, PhD, Maisarah Mokhtar, B.S, Tali Konry, PhD, Michael Levin, PhD, Andrew M. Evens, DO, MSc

Blood (2019) 134 (Supplement_1): 1511.

https://doi.org/10.1182/blood-2019-126539

Published: 2019

Journal Articles

Identification of FASN-Dependent Onco-Metabolic Regulation of the Pentose Phosphate Pathway (PPP) and Nucleotide Metabolism in Non-Hodgkin Lymphoma (NHL)

Ravi Dashnamoorthy, PhD, Afshin Beheshti, PhD, Xiaoyang Su, PhD, Ying Chen, PhD, Maisarah Mokhtar, B.S, Gregory Dolnikowski, Frederick Lansigan, MD, William B Kinlaw, III, MD, Sandeep Dave, MD, Andrew M. Evens, DO, MSc

Blood (2019) 134 (Supplement_1): 1573.

https://doi.org/10.1182/blood-2019-126382

Published: 2019

Journal Articles

Transcriptomic Systems Biology Analyses with Buparlisib (BKM120) Pan PI3K Inhibition in Canine B Cell Lymphoma (BCL): Leveraging Comparative Oncology for Cancer Therapeutics and Biomarker Discovery

Ravi Dashnamoorthy, PhD, Afshin Beheshti, PhD, Sarah Cass, BSVM, Athena Kritharis, MD, Kristine Burgess, DVM, MS, Cheryl London, DVM, PhD DACVIM, Andrew M. Evens, DO, MSc

Blood (2018) 132 (Supplement 1): 4114.

https://doi.org/10.1182/blood-2018-99-118548

Published: 2018

Journal Articles

Ultra-Sensitive Detection of Circulating Serum microRNAs (miRNAs) in Diffuse Large B-Cell Lymphoma (DLBCL) Patient-Derived Xenograft (PDX) Models and Correlation with Disease Status in DLBCL Patient

Afshin Beheshti, PhD, Kristen E. Stevenson, MS, Ravi Dashnamoorthy, PhD, Charles Vanderburg, PhD, David M Weinstock, MD, Andrew M. Evens, DO, MSc

Blood (2018) 132 (Supplement 1): 2973.

https://doi.org/10.1182/blood-2018-99-116789

Published: 2018

Journal Articles

Systems Biology Analyses to Delineate Mechanisms of Anti-CD20 Antibody Resistance in Non-Hodgkin Lymphoma (NHL): Influence of BCR Signaling and the Critical Importance of Calcium Polarization

Ravi Dashnamoorthy, PhD, Afshin Beheshti, PhD, Saheli Sarkar, PhD, Tali Konry, PhD, Michael Levin, PhD, Andrew M. Evens, DO, MSc

Blood (2018) 132 (Supplement 1): 1665.

https://doi.org/10.1182/blood-2018-99-118787

Published: 2018

Journal Articles

The Immune Checkpoint Receptors PD-1, PD-L1, TIM-3 and LAG-3 in Lymphoma: Tumor Cell and Tumor Infiltrating Lymphocyte (TIL) Expression, Patient Prognostication, and Identification of Rational Therapeutic Targets

Ravi Dashnamoorthy, PhD, Benjamin Chen, MD PhD, Pallavi Galera, Hong Chang, PhD, Afshin Beheshti, PhD, Srimoyee Ghosh, PhD, Andrew M Evens, DO,MSc

Blood (2017) 130 (Supplement 1): 2750.

https://doi.org/10.1182/blood.V130.Suppl_1.2750.2750

Published: 2017

Journal Articles

Harnessing Microfluidic Single Cell (MF-SC) and 3D "Organ-on-Chip" Assay Technologies for the Investigation of Immunotherapy and Study of Tumor Microenvironment (TME) in Antibody-Resistant Non-Hodgkin Lymphoma (NHL)

Ravi Dashnamoorthy, PhD, Saheli Sarkar, PhD, Pooja Sabachandani, MS, Sneha Purvey, MD, Afshin Beheshti, PhD, Tali Konry, PhD, Andrew M Evens, DO,MSc

Blood (2017) 130 (Supplement 1): 1473.

https://doi.org/10.1182/blood.V130.Suppl_1.1473.1473

Published: 2017

Journal Articles

Circulating Micrornas (miRNA) As a Novel Liquid Biopsy and Therapeutic Platform in MYC and Non-MYC Diffuse Large B-Cell Lymphoma (DLBCL)

Afshin Beheshti, PhD, Charles Vanderburg, PhD, Ravi Dashnamoorthy, PhD, John Tyson McDonald, PhD, Amanda L Christie, BS, Kay Shigemori, Hallie Jester, Hong Zhang, PhD, David M. Weinstock, MD, Andrew M Evens, DO,MSc

Blood (2017) 130 (Supplement 1): 4005.

https://doi.org/10.1182/blood.V130.Suppl_1.4005.4005

Published: 2017

Journal Articles

CD19-Chimeric Antigen Receptor (CAR) Engineered Natural Killer (NK) Cell Therapy: Novel "Off the Shelf" Immunotherapy in CD20 Resistant B-Cell Non-Hodgkin Lymphoma (NHL) Cell Lines, Primary NHL Cells, and a Human Lymphoma Xenograft Model

Sneha Purvey, MD, Ravi Dashnamoorthy, PhD, Afshin Beheshti, PhD, Andreas Klein, MD, Laurent Boissel, PhD, Saheli Sarkar, PhD, Tali Konry, PhD, Andrew M Evens, DO,MSc

Blood (2017) 130 (Supplement 1): 110.

https://doi.org/10.1182/blood.V130.Suppl_1.110.110

Published: 2017

Journal Articles

Proteasome and HDAC Inhibitor Therapy in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL): Nuclear Factor Erythroid 2 like 2 (NRF2)-Dependent Cell Death and Function

Frank C. Passero, Jr., MD, Ravi Dashnamoorthy, PhD, Afshin Beheshti, PhD, J. Tyson McDonald, PhD, Andrew M Evens, DO, MSc, FACP

Blood (2016) 128 (22): 3020.

https://doi.org/10.1182/blood.V128.22.3020.3020

Published: 2016

Journal Articles

Buparlisib/BKM120 PI3 Kinase Therapy in B Cell and T Cell Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL): Identification of Resistance Pathways and Biomarker Discovery

Afshin Beheshti, PhD, Michael E Coyle, MD, Ravi Dashnamoorthy, PhD, Andrew M Evens, DO, MSc, FACP

Blood (2016) 128 (22): 2920.

https://doi.org/10.1182/blood.V128.22.2920.2920

Published: 2016

Journal Articles

CD19 Target Activated Natural Killer (CD19.TaNK) Cellular Therapy: A Novel immunotherapeutic Approach to the Treatment of Non-Hodgkin Lymphoma (NHL)

Ravi Dashnamoorthy, PhD, Afshin Beheshti, PhD, Saheli Sarkar, PhD, Pooja Sabhachandani, Frank C. Passero, Jr., MD, Sneha Purvey, MD, Laurent Boissel, PhD, Tania Konry, Andrew M Evens, DO, MSc, FACP

Blood (2016) 128 (22): 4174.

https://doi.org/10.1182/blood.V128.22.4174.4174

Published: 2016

Journal Articles

The Proteasome Inhibitor, Ixazomib, Combined with Novel Drug Combinations in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL): Identification of Key Genes and Signaling Pathways Via a Novel Systems Biology Approach

Frank C. Passero, Jr., MD, Ravi Dashnamoorthy, PhD, Afshin Beheshti, PhD, Lynn Hlatky, PhD, Nassera Abermil, MS, PharmD, Michael E Coyle, MD, Jaya Sharma, MD MBBS, Andrew M. Evens, DO, MSc

Blood (2015) 126 (23): 2753.

https://doi.org/10.1182/blood.V126.23.2753.2753

Published: 2015

Journal Articles

The PI3 Kinase (PI3K) Inhibitor, Buparlisib/BKM120, in B-Cell, T-Cell and Hodgkin Lymphoma Cell Lines: Cell Death Studies and Examination of Genomic Pathway Analyses Via a Systems Biology Approach

Michael E Coyle, MD, Ravi Dashnamoorthy, PhD, Afshin Beheshti, PhD, Andrew M. Evens, DO, MSc

Blood (2015) 126 (23): 1555.

https://doi.org/10.1182/blood.V126.23.1555.1555

Published: 2015

Journal Articles

Lipid Addiction of Diffuse Large B-Cell Lymphoma (DLBCL): Fatty Acid Synthase (FASN) and PI3K Dependent Cell Death Identifies a Novel Therapeutic Paradigm

Ravi Dashnamoorthy, PhD, Afshin Beheshti, PhD, Nassera Abermil, MS, PharmD, Frederick Lansigan, MD, William Kinlaw, MD, Ron Gartenhaus, MD, Graham Jones, PhD DSc, Lynn Hlatky, PhD, Andrew M. Evens, DO, MSc

Blood (2015) 126 (23): 1284.

https://doi.org/10.1182/blood.V126.23.1284.1284

Published: 2015

Journal Articles

A Comparative Oncology Analysis of Canine T-Cell Lymphoma (TCL): Immunohistochemical Study and Next Generation Sequencing for Protein Analysis and Genomic Target Discovery

Athena Kritharis, MD, J. Tyson McDonald, PhD, Afshin Beheshti, PhD, Monika Pilichowska, MD, Kristine Burgess, DVM, MS, Luisel Ricks-Santi, PhD, Elizabeth McNiel, DVM, PhD, Ravi Dashnamoorthy, PhD, Andrew M. Evens, DO, MSc

Blood (2015) 126 (23): 3883.

https://doi.org/10.1182/blood.V126.23.3883.3883

Published: 2015

Journal Articles

The Lipid Addiction of Diffuse Large B-Cell Lymphoma (DLBCL) and Potential Treatment Strategies with Novel Fatty Acid Synthase (FASN) Small Molecule Inhibitors

Ravi Dashnamoorthy, PhD, Nassera Abermil, MS, PharmD, Afshin Behesti, PhD, Paige Kozlowski, BS, Frederick Lansigan, MD, William B Kinlaw, MD, Ronald Gartenhaus, MD, Graham Jones, PhD DSc, Lynn Hlatky, PhD, Andrew M. Evens, DO, MSc

Blood (2014) 124 (21): 4490.

https://doi.org/10.1182/blood.V124.21.4490.4490

Published: 2014

Journal Articles

A Comparative Oncology Study of Canine and Human Genomics and Proteomics in Peripheral T-Cell Lymphoma (PTCL): Examination of Shared Oncogenic Signaling for Biomarker and Therapeutic Target Discovery

Athena Kritharis, MD, Trent Fowler, PhD, Ravi Dashnamoorthy, PhD, Kristine E Burgess, DVM, MS, Afshin Beheshti, PhD, Nassera Abermil, MS, PharmD, Ananda Roy, PhD, Lynn Hlatky, PhD, Monika Pilichowska, MD, Elizabeth McNiel, DVM, PhD, Andrew M. Evens, DO, MSc

Blood (2014) 124 (21): 3019.

https://doi.org/10.1182/blood.V124.21.3019.3019

Published: 2014

Journal Articles

Genome-Wide Analysis Reveals MYC-Dependent Cell Death and Identifies Predictive Biomarkers of Ixazomib Sensitivity in Preclinical Models of T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL)

Ravi Dashnamoorthy, PhD, Afshin Behesti, PhD, Nassera Abermil, MS, PharmD, Jaya Sharma, MD MBBS, Michael Coyle, Irawati Kandela, PhD, Andrew Mazar, PhD, Lynn Hlatky, PhD, Andrew M. Evens, DO, MSc

Blood (2014) 124 (21): 3120.

https://doi.org/10.1182/blood.V124.21.3120.3120

Published: 2014

Journal Articles

The Bruton’s Tyrosine Kinase Inhibitor CC-292 in Diffuse Large B-Cell Lymphoma (DLBCL), T-Cell Lymphoma (TCL), and Hodgkin Lymphoma (HL): Induction of Cell Death and Examination of Rational Novel/Novel Therapeutic Combinations

Robert A. Cerulli, BS, Ravi Dashnamoorthy, PhD, Andrew M. Evens, DO, MSc

Blood (2014) 124 (21): 1772.

https://doi.org/10.1182/blood.V124.21.1772.1772

Published: 2014

NARROW

Transcriptomic and Metabolomic Profiling Identifies Calcium-Dependent Signaling Mechanisms As a Novel and Exploitable Target to Overcome Anti-CD20 Resistance in Non-Hodgkin Lymphoma (NHL)

Identification of FASN-Dependent Onco-Metabolic Regulation of the Pentose Phosphate Pathway (PPP) and Nucleotide Metabolism in Non-Hodgkin Lymphoma (NHL)

Transcriptomic Systems Biology Analyses with Buparlisib (BKM120) Pan PI3K Inhibition in Canine B Cell Lymphoma (BCL): Leveraging Comparative Oncology for Cancer Therapeutics and Biomarker Discovery

Ultra-Sensitive Detection of Circulating Serum microRNAs (miRNAs) in Diffuse Large B-Cell Lymphoma (DLBCL) Patient-Derived Xenograft (PDX) Models and Correlation with Disease Status in DLBCL Patient

Systems Biology Analyses to Delineate Mechanisms of Anti-CD20 Antibody Resistance in Non-Hodgkin Lymphoma (NHL): Influence of BCR Signaling and the Critical Importance of Calcium Polarization

The Immune Checkpoint Receptors PD-1, PD-L1, TIM-3 and LAG-3 in Lymphoma: Tumor Cell and Tumor Infiltrating Lymphocyte (TIL) Expression, Patient Prognostication, and Identification of Rational Therapeutic Targets

Harnessing Microfluidic Single Cell (MF-SC) and 3D "Organ-on-Chip" Assay Technologies for the Investigation of Immunotherapy and Study of Tumor Microenvironment (TME) in Antibody-Resistant Non-Hodgkin Lymphoma (NHL)

Circulating Micrornas (miRNA) As a Novel Liquid Biopsy and Therapeutic Platform in MYC and Non-MYC Diffuse Large B-Cell Lymphoma (DLBCL)

CD19-Chimeric Antigen Receptor (CAR) Engineered Natural Killer (NK) Cell Therapy: Novel "Off the Shelf" Immunotherapy in CD20 Resistant B-Cell Non-Hodgkin Lymphoma (NHL) Cell Lines, Primary NHL Cells, and a Human Lymphoma Xenograft Model

Proteasome and HDAC Inhibitor Therapy in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL): Nuclear Factor Erythroid 2 like 2 (NRF2)-Dependent Cell Death and Function

Buparlisib/BKM120 PI3 Kinase Therapy in B Cell and T Cell Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL): Identification of Resistance Pathways and Biomarker Discovery

CD19 Target Activated Natural Killer (CD19.TaNK) Cellular Therapy: A Novel immunotherapeutic Approach to the Treatment of Non-Hodgkin Lymphoma (NHL)

The Proteasome Inhibitor, Ixazomib, Combined with Novel Drug Combinations in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL): Identification of Key Genes and Signaling Pathways Via a Novel Systems Biology Approach

The PI3 Kinase (PI3K) Inhibitor, Buparlisib/BKM120, in B-Cell, T-Cell and Hodgkin Lymphoma Cell Lines: Cell Death Studies and Examination of Genomic Pathway Analyses Via a Systems Biology Approach

Lipid Addiction of Diffuse Large B-Cell Lymphoma (DLBCL): Fatty Acid Synthase (FASN) and PI3K Dependent Cell Death Identifies a Novel Therapeutic Paradigm

A Comparative Oncology Analysis of Canine T-Cell Lymphoma (TCL): Immunohistochemical Study and Next Generation Sequencing for Protein Analysis and Genomic Target Discovery

The Lipid Addiction of Diffuse Large B-Cell Lymphoma (DLBCL) and Potential Treatment Strategies with Novel Fatty Acid Synthase (FASN) Small Molecule Inhibitors

A Comparative Oncology Study of Canine and Human Genomics and Proteomics in Peripheral T-Cell Lymphoma (PTCL): Examination of Shared Oncogenic Signaling for Biomarker and Therapeutic Target Discovery

Genome-Wide Analysis Reveals MYC-Dependent Cell Death and Identifies Predictive Biomarkers of Ixazomib Sensitivity in Preclinical Models of T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL)

The Bruton’s Tyrosine Kinase Inhibitor CC-292 in Diffuse Large B-Cell Lymphoma (DLBCL), T-Cell Lymphoma (TCL), and Hodgkin Lymphoma (HL): Induction of Cell Death and Examination of Rational Novel/Novel Therapeutic Combinations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only